Navigation Links
Pharmaceutical Internal Communications Function Morphs to Address Corporate Priorities
Date:7/22/2011

CHAPEL HILL, N.C., July 22, 2011 /PRNewswire/ -- The structure of a biopharmaceutical company's Internal Communications group must evolve to reflect the changing goals and strategies. Realigning to support new corporate initiatives and establishing service levels to reflect priorities and resources are key improvement areas for Internal Communications executives in 2012.

"Differentiated services hold great value during times of resource reductions," according to "Internal Communications Excellence: Optimizing Group Structure & Operations," primary research conducted by Best Practices, LLC.

Download a complimentary white paper at http://www3.best-in-class.com/rr1094.htm that includes selected best practices drawn from extensive primary research with executives from 26 leading biopharmaceutical and medical device companies. The full 61-page report contains more than 100 benchmark metrics and 20 executive narratives, providing communications executives with organizational models and trends and insights about structure, staffing and investment levels.

Key insights include:

  • In the Pharma Segment, 52 percent of Internal Communications executives noted their group has a business unit focus while 48 percent have an enterprise-wide focus. Only 14 percent noted a product focus for the Internal Communications group.
  • While a majority of both biopharma and other industries favor a centralized approach for Internal Communications, a third of both takes a regional approach, where staff are placed in major regional offices (although a central group still resides at headquarters).

In conjunction with this study, "External Communications Excellence: Optimizing Group Structure & Operations," primary research conducted by Best Practices, LLC, addresses current trends in external communications with respect to its structural models, staffing and investment levels. A complimentary except is available at http://www3.best-in-class.com/rr1095.htm.

For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.  

BEST PRACTICES, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... A man who has struggled to quit smoking, a man who has struggled with hair ... solutions to his problems – and he did. Now Nabat, a serial entrepreneur featured as ... breakthrough inventions to the world and better people's lives. His own experience with nicotine addiction ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
Breaking Medicine News(10 mins):